bluebird bio Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : bluebird bio Inc.

BLUE 4.970

0.0%

Jun 2 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (64)	4/7/2014 10:26:58 AM
From: Biotech Jim	Read Replies (1) of 163

tuck- Thanks for posting that as I had not seen that. I have been away from the biotech news for the last few days as I am helping a friend collect sap and making maple syrup in north central Wisconsin. These 'transformational' therapies are great/phenomenal when they work, but very risky for the trial participants. And some people want these therapies to be approved too early. Good luck to all the patients involved. From the article you posted: "Six patients died of either disease relapse or progression, said MSK, while two patients died in remission from complications related to allogeneic bone marrow transplantation. An additional two patients died within two weeks of receiving a CAR-T cell infusion." The complications from allogeneic bone marrow transplants could be from the drugs used for GVHD like cyclosporin or others, or could be due to microangiopathic hemolytic anemia (MAHA) via endothelial damage. The early adverse effects could be due to the cytokine release syndrome I mentioned earlier. For MAHA, see: http://europepmc.org/abstract/MED/1768975/reload=0;jsessionid=u1kJzCgEfzH7QAviyh1S.18 BJ

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next